All quotations are from the companies' most recent S-1 filings with links provided.
We are an orthopedic implants company focused on using our silicon nitride ceramic technologies to develop, manufacture and commercialize a broad range of advanced, high-performance spine and joint implants. We have developed a formulation of silicon nitride which we believe has the strength, toughness and wear resistance necessary to overcome the limitations of currently available orthopedic implants. Upon introduction to market, we believe our implants will represent the first commercial use of silicon nitride ceramics in orthopedic applications and will have the potential to provide an improved combination of characteristics, including greater strength and resistance to fracture, improved resistance to wear, greater ability to promote bone attachment and better compatibility with surgical and diagnostic imaging. Based on these potential advantages, we believe our silicon nitride product candidates may achieve better long-term clinical outcomes with enhanced durability, longevity, biocompatibility and patient fit. While we have not received regulatory clearance or approval for any of our product candidates that we intend to commercialize, in the second half of 2007 we expect to submit premarket notifications to the U.S. Food and Drug Administration, or the FDA, seeking regulatory clearance of our first commercial product candidate. Our goal is to establish our silicon nitride implants as new standards of care for the largest and fastest growing orthopedic implant markets: the spine, hip and knee markets.
Offering: 4.7 million shares at $13.00 - $15.00 per share. Net proceeds of approximately $57.8 million will be used
to fund the development and commercialization of our lead products, to build our sales, marketing and distribution capabilities, to establish commercial-scale manufacturing operations, to fund research and development activities for our pipeline product candidates, to increase our working capital, to create a public market for our common stock, to increase our ability to access the capital markets in the future, to provide liquidity for our existing stockholders, and for general corporate purposes.
Lead Underwriters: Morgan Stanley, Jefferies
We recorded no grant revenue in either period due to our internal product development projects in 2006 and 2007, which were not related to our existing grants. We were awarded an $800,000 NIH grant in late 2006, for which we expect to begin recognizing revenue in the second half of 2007 as we provide services under the related grant contract... The increase in research and development expense in the three months ended March 31, 2007 [$1,479,340] compared to the same period in 2006 [$1,100,125] was due primarily to an increase in salaries and benefits of approximately $130,000, including the hiring of one additional person, an increase of approximately $180,000 from depreciation due to additional equipment in our manufacturing facility, and an increase in rent of $90,000 for our new manufacturing facility... The increase in general and administrative expenses for the three months ended March 31, 2007 [$405,380] compared to the same period in 2006 [$184,425] was due primarily to an additional $215,000 in legal fees incurred in the three months ended March 31, 2007 in connection with a review of our intellectual property position.
We are an independent oil and natural gas company engaged in the acquisition, development, exploitation and exploration of oil and natural gas properties. Our conventional operations are primarily focused in the Permian Basin of Southeast New Mexico and West Texas. These conventional operations are complemented by our activities in unconventional emerging resource plays. We intend to grow our reserves and production through development drilling, exploitation and exploration activities on our multi-year project inventory and through acquisitions that meet our strategic and financial objectives.
Offering: 21.2 million shares at $14.00 - $16.00 per share. Net proceeds of approximately $183.2 million will be used repay a portion of the company's outstanding indebtedness under a second lien term loan facility, revolving credit facility or a combination of the foregoing.
Lead Underwriters: J.P. Morgan, Banc of America
Revenue from oil and gas operations increased by $143.4 million (261%) from $54.9 million for the year ended December 31, 2005 to $198.3 million for the year ended December 31, 2006... Production expenses (including production taxes) increased $23.2 million (159%) from $14.6 million ($2.09 per Mcfe) to $37.8 million ($1.62 per Mcfe) for the years ended December 31, 2005 and 2006, respectively... Exploration and abandonments / geological and geophysical costs increased by $2.9 million from $2.7 million during 2005 to $5.6 million during 2006... We recorded income tax expense of $2.0 million and $14.4 million for the years ended December 31, 2005 and 2006, respectively.
We are a leading provider of necessary business information and professional services to the legal, financial and real estate sectors in the United States. We provide companies and professionals in the markets we serve with access to timely, relevant and dependable information and services that enable them to operate effectively in highly competitive and time sensitive business environments. We serve our customers through two complementary operating divisions: Business Information and Professional Services.
Offering: 10.5 million shares at $13.50 - $15.50 per share. Net proceeds of approximately $138,592,500 will be used to redeem outstanding shares of series A and B preferred stock, to repay debt and for general corporate purposes.
Lead Underwriters: Goldman Sachs, Merrill Lynch
Our total revenues increased $33.8 million, or 43.4%, to $111.6 million in 2006 ($127.7 million on a pro forma basis) from $77.9 million in 2005... Our total operating expenses increased $23.2 million, or 33.3%, to $92.7 million in 2006 ($107.1 million on a pro forma basis) from $69.5 million in 2005... Interest expense, net increased $4.6 million to $6.4 million in 2006 ($8.5 million on a pro forma basis) from $1.9 million in 2005... We previously were engaged in the business of in-bound and out-bound teleservices. In September 2005, we sold our telemarketing operations to management personnel of this operating unit and incurred a $1.8 million loss, net of tax benefit, from discontinued operations in 2005. We did not incur a corresponding loss in 2006.